Bio-Rad

Historical price data

Bio-Rad Laboratories operates a resilient, dual-segment business model spanning Life Science research tools and Clinical Diagnostics systems. The company has established a formidable competitive moat through its proprietary Droplet Digital PCR (ddPCR) technology, which has become a gold standard for high-sensitivity nucleic acid quantification. Its strategy focuses on providing essential, high-value tools that drive discovery and ensure diagnostic accuracy, balancing exposure to research funding cycles with the stable, regulated diagnostics market. With a 70+ year history, Bio-Rad is a foundational, publicly traded entity in the global biotech and healthcare infrastructure.

Bio-Rad's core platform is Droplet Digital PCR (ddPCR), which partitions samples into thousands of droplets for absolute, ultra-sensitive quantification of nucleic acids. The company also maintains strong platforms in process chromatography, western blotting, flow cytometry, and automated clinical diagnostics systems.

Bio-Rad competes with giants like Thermo Fisher and Danaher across life science tools, and with Roche and Abbott in diagnostics. Its key advantage is deep expertise and leadership in niche, high-value technologies like Droplet Digital PCR, though it must constantly innovate to defend these positions.